Journal of neurology · 2025
Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moiola Lucia, Mandelli Alessandra, Tarkowski Maciej, Finardi Annamaria, Gabrieli Arianna, Zanetta Chiara, Viti Vittorio, Gattuso Irene, Esposito Federica, Pedotti Rosetta, Muros-Le Rouzic Erwan, Raposo Catarina, Rocca Maria A, Locatelli Massimo, Bonini Chiara, Furlan Roberto, Riva Agostino, Filippi Massimo
Аннотация
BACKGROUND: Utility of repeated boosts of anti-SARS-CoV-2 vaccination in persons with MS (pwMS) treated with ocrelizumab is questioned.
OBJECTIVE: Investigate antiviral antibody and T-cell responses after mRNA vaccination for SARS-CoV-2 in ocrelizumab-treated pwMS.
METHODS: Peripheral blood mononuclear cells were stimulated with SARS-CoV-2 peptide pools and T-cell reactivity was assessed by ELISPOT for IFN-γ detection, and by multiparametric flow cytometry analyses for assessment and characterization of T-cell activation. Anti-SARS-CoV-2 spike and nucleocapsid antibodies were analyzed in plasma of pwMS using two commercial platforms.
RESULTS: ELISPOT assay against the spike protein of SARS-CoV-2 showed that COVID vaccination with mRNA results in the development of a robust specific T-cell reactivity that is sustained over repeated cycles of vaccination and tends to decline 2 years after last boost. Flow cytometry analysis following stimulation with SARS-CoV-2 peptide pools confirmed the presence of CD8+ T memory stem cells. CD8+ T memory stem cells, in particular, increased after repeated boosts of vaccination, as occurred for anti-SARS-CoV-2 antibodies.
CONCLUSIONS: Repeated cycles of vaccination increase T and B-cell reactivity against SARS-CoV-2.
OBJECTIVE: Investigate antiviral antibody and T-cell responses after mRNA vaccination for SARS-CoV-2 in ocrelizumab-treated pwMS.
METHODS: Peripheral blood mononuclear cells were stimulated with SARS-CoV-2 peptide pools and T-cell reactivity was assessed by ELISPOT for IFN-γ detection, and by multiparametric flow cytometry analyses for assessment and characterization of T-cell activation. Anti-SARS-CoV-2 spike and nucleocapsid antibodies were analyzed in plasma of pwMS using two commercial platforms.
RESULTS: ELISPOT assay against the spike protein of SARS-CoV-2 showed that COVID vaccination with mRNA results in the development of a robust specific T-cell reactivity that is sustained over repeated cycles of vaccination and tends to decline 2 years after last boost. Flow cytometry analysis following stimulation with SARS-CoV-2 peptide pools confirmed the presence of CD8+ T memory stem cells. CD8+ T memory stem cells, in particular, increased after repeated boosts of vaccination, as occurred for anti-SARS-CoV-2 antibodies.
CONCLUSIONS: Repeated cycles of vaccination increase T and B-cell reactivity against SARS-CoV-2.